Chris Lievens, OD, MS, FAAO, FNAP
Preservatives may disrupt the ocular surface, contributing to poor adherence.
The world’s population is aging, resulting in an increase in the geriatric demographic, leading to a rise in certain diseases, including glaucoma. It is estimated that approximately 3 million Americans are currently being treated for glaucoma and this number is expected to double by 2050.3 The Glaucoma Research Foundation reports a dramatic increase in glaucoma diagnosis in patients over 60 years4; coupled with an estimated life expectancy in the US of 77.5 years,5 this means that most patients with glaucoma are relying on topical antiglaucoma medications for years, if not decades. The risk of developing ocular surface complications increases with the duration of topical therapy use and the number of preserved topical therapies a patient uses. As optometrists, we should be mindful of these ocular surface issues and prescribe with patient compliance, comfort, and quality of life in mind…..
Read more: rb.gy/f6iyfa
Source: Optometry Times